News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RedHill Biopharma Ltd. (RDHL) Announces Positive Preliminary Pre-Clinical Data With RHB-104 For The Treatment Of Type 1 Diabetes


6/26/2014 7:19:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TEL-AVIV, Israel, June 26, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer, today announced preliminary positive data from a pre-clinical study with RHB-104 for the treatment of type 1 diabetes, a chronic autoimmune disease with an unknown cause. In light of the preliminary positive data, and subject to the final results and an independent report expected in the coming weeks, the Company is currently assessing the next steps in the development program, including a possible Phase II proof of concept clinical study for type 1 diabetes.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES